Catalent to Commercially Supply Palatin FSD Pen Injectors
PTSM: Pharmaceutical Technology Sourcing and Management
The pen injectors will be produced at Catalent’s Brussels, Belgium facility.
Catalent Pharma Solutions and Palatin Technologies have reached a commercial supply agreement to support the launch of Palatin’s bremelanotide pen injector product, which is used to treat female sexual dysfunction (FSD), Catalent said in a June 30, 2016 press announcement. Bremelanotide is a subcutaneous injectable peptide melanocortin receptor agonist and is designed to treat hypoactive sexual desire disorder, the most common form of FSD, in premenopausal women. The bremelanotide pen injectors will be produced at Catalent's 265,000-sq.-ft. Brussels, Belgium facility, Catalent noted. Phase III trials of bremelanotide are currently ongoing, with launch anticipated in 2018.
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
